Imiquimod for Genital Herpes Treatment

Introduction to Imiquimod

The Centers for Disease Control and Prevention recommends that imiquimod is not used as a primary treatment for genital herpes but may be considered as an alternative therapy for acyclovir-resistant HSV infections 1, 2

Imiquimod is a topically active immune enhancer that stimulates production of interferon and other cytokines, but it is not FDA-approved for genital herpes treatment 3
It is primarily approved and recommended for treatment of external genital warts, not genital herpes 3, 4
The Centers for Disease Control and Prevention recommends standard treatment for genital herpes includes oral antiviral medications such as acyclovir, valacyclovir, or famciclovir 2

Case reports suggest that imiquimod may be useful in the treatment of acyclovir-resistant HSV infections 1, 5
In immunocompromised patients with acyclovir-resistant HSV, intravenous foscarnet is the treatment of choice, but topical imiquimod has been used successfully for lesions on external surfaces 2

When used for genital warts (its approved indication), imiquimod 5% cream is applied once daily at bedtime, three times a week for up to 16 weeks 3, 6
Common side effects include local inflammatory reactions such as redness, irritation, induration, ulceration/erosions, and vesicles 6
Imiquimod might weaken condoms and vaginal diaphragms 6
The safety of imiquimod during pregnancy has not been established 3, 6

The Centers for Disease Control and Prevention recommends first-line treatment for genital herpes should be oral antiviral medications (acyclovir, valacyclovir, or famciclovir) for both episodic and suppressive therapy 2
Imiquimod should only be considered when standard antiviral treatments have failed or in cases of confirmed acyclovir resistance 2

For standard genital herpes treatment, use FDA-approved antiviral medications (acyclovir, valacyclovir, or famciclovir) 2
Reserve imiquimod for cases of documented acyclovir resistance when standard treatments have failed 1, 2
Consider consultation with infectious disease specialists for management of acyclovir-resistant HSV infections 2